The presence of a significant association between elevated PRV‐1 mRNA expression and low plasma erythropoietin concentration in essential thrombocythaemia

Abstract

Approximately 45% of newly diagnosed patients with essential thrombocythaemia (ET) demonstrate subnormal plasma erythropoietin (EPO) concentrations, which constitutes a risk factor for occlusive vascular events. In 58 ET patients, a possible association between polycythaemia rubra vera-1 (PRV-1) overexpression and subnormal plasma EPO was investigated, which was always measured prior to the institution of platelet lowering agents. At the time when PRV-1 expression was measured, 28 of 58 (48%) ET patients had received platelet lowering treatment. PRV-1 expression was measured by quantitative real-time reverse transcription-polymerase chain reaction assay of mRNA extracted from purified peripheral blood buffy coat. The cycle threshold (CT) value of PRV-1 was determined and was divided with the CT value for the housekeeping GAPDH gene transcript. A quotient <0.93 was defined as PRV-1 positive. Of the ET patients 12 of 58 (21%) were PRV-1 positive and 19 of 58 (33%) demonstrated subnormal plasma EPO. In the 58 ET patients there was a significant association between low plasma EPO and PRV-1 positive results (P = 0.001). The 30 ET patients who had not received any platelet lowering treatment showed a significant (P = 0.005) relation between PRV-1 positivity and subnormal plasma EPO. No such relationship was present in the 28 ET patients who had received prior treatment with the above drugs (P = 0.147).

Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis

“…PRV1 is a hematopoietic cell surface receptor that has been shown to transduce intracellular signals leading to proliferation, involving JAK2 and Src kinases [16]. PRV1 is overexpressed in MPN patients [15,19,41,42] and seems to be associated with PV disease phenotype characterized by high erythrocyte and low platelet counts [15]. These studies also described a correlation between PRV1 expression and the JAK2 V617F allele burden, as well as between PRV1 overexpression and elevated JAK2 tyrosine kinase activity [15,19,25,41,42].…”

Clinical significance of neutrophil CD177 mRNA expression in Ph‐negative chronic myeloproliferative disorders

“…Considering the values for sensitivity and specificity reported in Table II, it can be concluded that the current conventional tests are, at least, equally useful (Messinezy et al , 2002; Zwicky et al , 2002). It remains to be established whether evaluation of neutrophil CD177 mRNA may be employed for defining prognosis (Johansson et al , 2003) or monitoring disease activity in the individual patient with CMD.…”

Initial (Latent) Polycythemia vera with Thrombocytosis Mimicking Essential Thrombocythemia

“…Moreover, in a considerable number of patients with ET a significant association between a low erythropoietin level and an elevated PVR-1 gene expression was described [36]. Although the occurrence of this concurrent marker profile was recognized to a far lesser degree in other series [37, 38], it has been suggested that two types of ET may be distinguished [35, 39] and that PVR-1-positive ET reveals a higher risk for vascular complications [40].…”